Human V γ9Vδ2 T cells show potent antitumor activity against zoledronate-sensitized OSCC cell lines.

CONCLUSIONS: We found that zoledronate-treated OSCC cell lines are effectively killed by Vγ9Vδ2 T cells. Our results indicate that developing Vγ9Vδ2 T cell-based immunotherapy will be promising in treating patients with OSCC.
PMID: 30722122 [PubMed - in process]

Source: Journal of B.U.ON. - February 7, 2019 Category: Cancer & Oncology Tags: J BUON Source Type: research